Search results

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.

Result type

Technology appraisal guidance

Published

25 May 2016

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.

Result type

Technology appraisal guidance

Published

1 February 2016

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

Result type

Technology appraisal guidance

Published

18 February 2016

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary (heterozygous-familial and non-familial) hypercholesterolaemia in adults.

Result type

Technology appraisal guidance

Published

24 February 2016

Evidence-based recommendations on ciclosporin (Ikervis) for dry eye disease in adults that has not improved despite treatment with artificial tears.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on erlotinib (Tarceva) and gefitinib (Iressa) for treating non-small-cell lung cancer after chemotherapy in adults.

Result type

Technology appraisal guidance

Published

16 December 2015

Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

Result type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Result type

Technology appraisal guidance

Published

27 January 2016

NICE was unable to make recommendations on eltrombopag (Revolade) for severe aplastic anaemia refractory to immunosuppressive therapy because no evidence submission was received from Novartis, but will review this decision if the company decides to make a submission

Result type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

Result type

Technology appraisal guidance

Published

25 November 2015

Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events, such as heart attack and stroke, after acute coronary syndrome in adults.

Result type

Technology appraisal guidance

Published

25 March 2015

Evidence-based recommendations on empagliflozin (Jardiance) in combination therapy for treating type 2 diabetes.

Result type

Technology appraisal guidance

Published

25 March 2015

Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

Result type

Technology appraisal guidance

Published

8 June 2015